Identification of Purines and 7-Deazapurines as Potent and Selective Type i Inhibitors of Troponin I-Interacting Kinase (TNNI3K)

Journal of Medicinal Chemistry

Volumn 58, Issue 18, 2015, Pages 7431-7448

  Lawhorn, Brian G ^a   Philp, Joanne ^a   Zhao, Yongdong ^a   Louer, Christopher ^a   Hammond, Marlys ^a   Cheung, Mui ^a   Fries, Harvey ^a   Graves, Alan P ^a   Shewchuk, Lisa ^a   Wang, Liping ^a   Cottom, Joshua E ^a   Qi, Hongwei ^a   Zhao, Huizhen ^a   Totoritis, Rachel ^a   Zhang, Guofeng ^a   Schwartz, Benjamin ^a   Li, Hu ^a   Sweitzer, Sharon ^a   Holt, Dennis A ^a   Gatto, Gregory J ^a   Kallander, Lara S ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(9H PURIN 6 YL)AMINO] N METHYLBENZENESULFONAMIDE; 7 DEAZAPURINE DERIVATIVE; BENZENESULFONAMIDE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; PURINE DERIVATIVE; TROPONIN I INTERACTING KINASE; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN BINDING; SULFONAMIDE; TNNI3K PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME BINDING; ENZYME INHIBITION; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; HUMAN; ORAL DRUG ADMINISTRATION; PROTEIN CONFORMATION; SPRAGUE DAWLEY RAT; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MALE; MAP KINASE KINASE KINASES; PROTEIN BINDING; PROTEIN CONFORMATION; PURINES; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84942279582     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00931     Document Type: Article

References (51)

1. Zhao, Y.; Meng, X. M.; Wei, Y. J.; Zhao, X. W.; Liu, D. Q.; Cao, H. Q.; Liew, C. C.; Ding, J. F. Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin I J. Mol. Med. (Berl) 2003, 81, 297-304
2. Lal, H.; Ahmad, F.; Parikh, S.; Force, T. Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease Circ. J. 2014, 78, 1514-1519 10.1253/circj.CJ-14-0543
3. Vagnozzi, R. J.; Gatto, G. J., Jr.; Kallander, L. S.; Hoffman, N. E.; Mallilankaraman, K.; Ballard, V. L. T.; Lawhorn, B. G.; Stoy, P.; Philp, J.; Graves, A. P.; Naito, Y.; Lepore, J. J.; Gao, E.; Madesh, M.; Force, T. Inhibition of the cardiomyocyte-specific TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart Sci. Transl. Med. 2013, 5, 207ra141 10.1126/scitranslmed.3006479
4. Wang, L.; Wang, H.; Ye, J.; Xu, R. X.; Song, L.; Shi, N.; Zhang, Y. W.; Chen, X.; Meng, X. M. Adenovirus-mediated overexpression of cardiac troponin I-interacting kinase promotes cardiomyocyte hypertrophy Clin. Exp. Pharmacol. Physiol. 2011, 38, 278-284 10.1111/j.1440-1681.2011.05499.x
5. Wheeler, F. C.; Tang, H.; Marks, O. A.; Hadnott, T. N.; Chu, P. L.; Mao, L.; Rockman, H. A.; Marchuk, D. A. Tnni3k modifies disease progression in murine models of cardiomyopathy PLoS Genet. 2009, 5, e1000647 10.1371/journal.pgen.1000647
6. Stoy, P. unpublished results.
7. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitiative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-131 10.1038/nbt1358
8. Fabian, M. A.; Biggs, W. H., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-335 10.1038/nbt1068
9. Harris, I. S.; Zhang, S.; Treskov, I.; Kovacs, A.; Weinheimer, C.; Muslin, A. J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload Circulation 2004, 110, 718-723 10.1161/01.CIR.0000138190.50127.6A
10. Muslin, A. J. Role of Raf proteins in cardiac hypertrophy and cardiomyocyte survival Trends Cardiovasc. Med. 2005, 15, 225-229 10.1016/j.tcm.2005.06.008
11. Gonnella, N. C.; Roberts, J. D. Studies of the tautomerism of purine and the protonation of purine and its 7- and 9-methyl derivatives by nitrogen-15 nuclear magnetic resonance spectroscopy J. Am. Chem. Soc. 1982, 104, 3162-3164 10.1021/ja00375a038
12. Leung, C. S.; Leung, S. S. F.; Tirado-Rives, J.; Jorgensen, W. L. Methyl effects on protein-ligand binding J. Med. Chem. 2012, 55, 4489-4500 10.1021/jm3003697
13. Schmid, S.; Rottgen, M.; Thewalt, U.; Austel, V. Synthesis and conformational properties of 2,6-bis-anilino-3-nitropyridines Org. Biomol. Chem. 2005, 3, 3408-3421 10.1039/b508819b
14. Uno, B.; Kawakita, T.; Kano, K.; Ezumi, K.; Kubota, T. Spectroscopic analysis and geometry assignment of the minimum energy conformations of 2-phenoxypyridines and diphenyl ethers Bull. Chem. Soc. Jpn. 1992, 65, 2697-2703 10.1246/bcsj.65.2697
15. King, A. J.; Patrick, D. R.; Batorsky, R. S.; Ho, M. L.; Do, H. T.; Zhang, S. Y.; Kumar, R.; Rusnak, D. W.; Takle, A. K.; Wilson, D. M.; Hugger, E.; Wang, L.; Karreth, F.; Lougheed, J. C.; Lee, J.; Chau, D.; Stout, T. J.; May, E. W.; Rominger, C. M.; Schaber, M. D.; Luo, L.; Lakdawala, A. S.; Adams, J. L.; Contractor, R. G.; Smalley, K. S. M.; Herlyn, M.; Morrissey, M. M.; Tuveson, D. A.; Huang, P. S. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885 Cancer Res. 2006, 66, 11100-11105 10.1158/0008-5472.CAN-06-2554
16. Ahlbrecht, H.; Duber, E. O.; Epsztajn, J.; Marcinkowski, R. M. K. Delocalisation, conformation and basicity of anilines Tetrahedron 1984, 40, 1157-1165 10.1016/S0040-4020(01)99321-4
17. Zhang, C.; Shokat, K. M. Enhanced selectivity for inhibition of analog sensitive kinases through scaffold optimization Tetrahedron 2007, 63, 5832-5838 10.1016/j.tet.2007.02.089
18. Tasler, S.; Muller, O.; Wieber, T.; Herz, T.; Krauss, R.; Totzke, F.; Kubbutat, M. H. G.; Schachtele, C. N-substituted 2′-(aminoaryl)benzothiazoles as kinase inhibitors: Hit identification and scaffold hopping Bioorg. Med. Chem. Lett. 2009, 19, 1349-1356 10.1016/j.bmcl.2009.01.054
19. Liu, X.-P.; Narla, R. K.; Uckun, F. M. Organic phenyl arsonic acid compounds with potent antileukemic activity Bioorg. Med. Chem. Lett. 2003, 13, 581-583 10.1016/S0960-894X(02)00928-9
20. Bridges, A. J.; Denny, W. A.; Fry, D.; Kraker, A.; Meyer, R. F.; Rewcastle, G. W.; Thompson, A. M. Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family. U.S. Patent 5,654,307, 1997.
21. Gangjee, A.; Namjoshi, O. A.; Ihnat, M. A.; Buchanan, A. The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines Bioorg. Med. Chem. Lett. 2010, 20, 3177-3181 10.1016/j.bmcl.2010.03.064
22. Deng, X.; Okram, B.; Ding, Q.; Zhang, J.; Choi, Y.; Adrian, F. J.; Wojciechowski, A.; Zhang, G.; Che, J.; Bursulaya, B.; Cowan-Jacob, S. W.; Rummel, G.; Sim, R.; Gray, N. S. Expanding the diversity of allosteric Bcr-Abl inhibitors J. Med. Chem. 2010, 53, 6934-6946 10.1021/jm100555f
23. 5erbB) tyrosine kinases Bioorg. Med. Chem. Lett. 2002, 12, 2153-2157 10.1016/S0960-894X(02)00364-5
24. Voronkov, M. V.; Gu, K.; Baugh, S. D. P.; Becker, M. R. A modular approach to 4,5-diaminopyrrolo[2,3-d]pyrimidines and 2,4,5-triaminopyrrolo[2,3-d]pyrimidines Tetrahedron Lett. 2006, 47, 4149-4151 10.1016/j.tetlet.2006.04.060
25. Guillard, J.; Decrop, M.; Gallay, N.; Espanel, C.; Boissier, E.; Herault, O.; Viaud-Massuard, M.-C. Synthesis and biological evaluation of 7-azaindole derivatives, synthetic cytokinin analogues Bioorg. Med. Chem. Lett. 2007, 17, 1934-1937 10.1016/j.bmcl.2007.01.033
26. Girgis, N. S.; Larson, S. B.; Robins, R. K.; Cottam, H. B. The synthesis of 5-azaindoles by substitution-rearrangement of 7-azaindoles upon treatment with certain primary amines J. Heterocycl. Chem. 1989, 26, 317-325 10.1002/jhet.5570260210
27. Axten, J. M.; Romeril, S. P.; Shu, A.; Ralph, J.; Medina, J. R.; Feng, Y.; Li, W. H. H.; Grant, S. W.; Heerding, D. A.; Minthorn, E.; Mencken, T.; Gaul, N.; Goetz, A.; Stanley, T.; Hassell, A. M.; Gampe, R. T.; Atkins, C.; Kumar, R. Discovery of GSK2656157: An optimized PERK inhibitor selected for preclinical development ACS Med. Chem. Lett. 2013, 4, 964-968 10.1021/ml400228e
28. Devine, S. M.; Lim, S. S.; Chandrashekaran, I. R.; Macraild, C. A.; Drew, D. R.; Debono, C. O.; Lam, R.; Anders, R. F.; Beeson, J. G.; Scanlon, M. J.; Scammells, P. J.; Norton, R. S. A critical evaluation of pyrrolo[2,3-d]pyrimidine-4-amines as Plasmodium falciparum apical membrane antigen 1 (AMA1) inhibitors MedChemComm 2014, 5, 1500-1506 10.1039/C4MD00090K
29. Reader, J. C.; Matthews, R. P.; Klair, S.; Cheung, K.-M. J.; Scanlon, J.; Proisy, N.; Addison, G.; Ellard, J.; Piton, N.; Taylor, S.; Cherry, M.; Fisher, M.; Boxall, K.; Burns, S.; Walton, M. I.; Westwood, I. M.; Hayes, A.; Eve, P.; Valenti, M.; De Haven Brandon, A.; Box, G.; Van Montfort, R. L. M.; Williams, D. H.; Aherne, G. W.; Raynaud, F. I.; Eccles, S. A.; Garrett, M. D.; Collins, I. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing J. Med. Chem. 2011, 54, 8328-8342 10.1021/jm2007326
30. Khalaf, A. I.; Huggan, J. K.; Suckling, C. J.; Gibson, C. L.; Stewart, K.; Giordani, F.; Barrett, M. P.; Wong, P. E.; Barrack, K. L.; Hunter, W. N. Structure-based design and synthesis of antiparasitic pyrrolopyrimidines targeting pteridine reductase 1 J. Med. Chem. 2014, 57, 6479 10.1021/jm500483b
31. Pudlo, J. S.; Nassiri, M. R.; Kern, E. R.; Wotring, L. L.; Drach, J. C.; Townsend, L. B. Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines J. Med. Chem. 1990, 33, 1984-1992 10.1021/jm00169a028
32. Wang, X.; Seth, P. P.; Ranken, R.; Swayze, E. E.; Migawa, M. T. Synthesis and biological activity of 5-fluorotubercidin Nucleosides, Nucleotides Nucleic Acids 2004, 23, 161-170 10.1081/NCN-120027825
33. Pudlo, J. S.; Saxena, N. K.; Nassiri, M. R.; Turk, S. R.; Drach, J. C.; Townsend, L. B. Synthesis and antiviral activity of certain 4- and 4,5-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines J. Med. Chem. 1988, 31, 2086-2092 10.1021/jm00119a006
34. Showalter, H. D. H.; Bridges, A. J.; Zhou, H.; Sercel, A. D.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and [4,5-b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase J. Med. Chem. 1999, 42, 5464-5474 10.1021/jm9903949
35. Reader, J. C.; Matthews, T. P.; Klair, S.; Cheung, K.-M. J.; Scanlon, J.; Proisy, N.; Addison, G.; Ellard, J.; Piton, N.; Taylor, S.; Cherry, M.; Fisher, M.; Boxall, K.; Burns, S.; Walton, M. I.; Westwood, I. M.; Hayes, A.; Eve, P.; Valenti, M.; Brandon, A. d. H.; Box, G.; van Montfort, R. L. M.; Williams, D. H.; Aherne, G. W.; Raynaud, F. I.; Eccles, S. A.; Garrett, M. D.; Collins, I. Structure guided evolution of potent and selective CHK1 inhibitors through scaffold morphing J. Med. Chem. 2011, 54, 8328-8342 10.1021/jm2007326
36. Mincione, F.; Menabuoni, L.; Briganti, F.; Mincione, G.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IV with N-hydroxysulfonamides-a novel class of intraocular pressure lowering agents J. Enzyme Inhib. 1998, 13, 267-284 10.3109/14756369809021475
37. Petrow, V.; Stephenson, O.; Wild, A. M. Studies in the field of diuretic agents part V. A new route to disulphamyl derivatives of benzene J. Pharm. Pharmacol. 1960, 12, 705-719 10.1111/j.2042-7158.1960.tb12736.x
38. Mayasundari, A.; Fujii, N. Efficient formation of 4,6-disubstituted pyrollo[2,3-d]pyrimidines: a novel route to TWS119, a glycogen synthase kinase-3β inhibitor Tetrahedron Lett. 2010, 51, 3597-3598 10.1016/j.tetlet.2010.05.032
39. Clark, M. P.; George, K. M.; Bookland, R. G.; Chen, J.; Laughlin, S. K.; Thakur, K. D.; Lee, W.; Davis, J. R.; Cabrera, E. J.; Brugel, T. A.; VanRens, J. C.; Laufersweiler, M. J.; Maier, J. A.; Sabat, M. P.; Golebiowski, A.; Easwaran, V.; Webster, M. E.; De, B.; Zhang, G. Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3) Bioorg. Med. Chem. Lett. 2007, 17, 1250 10.1016/j.bmcl.2006.12.018
40. Abdel-Magid, A. F.; Carson, K. C.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive amination of aldehydes and ketones with sodium triacetoxyborohoydride. Studies on direct and indirect reductive amination procedures J. Org. Chem. 1996, 61, 3849-3862 10.1021/jo960057x
41. Sabatucci, J. P.; Ashwell, M. A.; Trybulski, E.; O'Donnell, M.-M.; Moore, W. J.; Harnish, D. C.; Chadwick, C. C. Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands Bioorg. Med. Chem. Lett. 2006, 16, 854-858 10.1016/j.bmcl.2005.11.015
42. Morisawa, Y.; Kataoka, M.; Nagahori, H.; Sakamoto, T.; Kitano, N.; Kusano, K.; Sato, K. Studies on anticoccidial agents. 13. Synthesis and anticoccidial activity of nitropyridine-2- and -3-sulfonamides and derivatives J. Med. Chem. 1980, 23, 1376-1380 10.1021/jm00186a017
43. Wendt, M. D.; Shen, W.; Kunzer, A.; McClellan, W. J.; Bruncko, M.; Oost, T. K.; Ding, H.; Joseph, M. K.; Zhang, H.; Nimmer, P. N.; Ng, S.-C.; Shoemaker, A. R.; Petros, A. M.; Oleksijew, A.; Marsh, K.; Bauch, J.; Oltersdorf, T.; Belli, B. A.; Martineau, D.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo J. Med. Chem. 2006, 49, 1165-1181 10.1021/jm050754u
44. For an example of using the H-bond donating ability of a gatekeeper Thr to introduce kinase selectivity, see: Martin, M. W.; Newcomb, J.; Nunes, J. J.; Boucher, C.; Chai, L.; Epstein, L. F.; Faust, T.; Flores, S.; Gallant, P.; Gore, A.; Gu, Y.; Hsieh, F.; Huang, X.; Kim, J. L.; Middleton, S.; Morgenstern, K.; Oliveira-dos-Santos, A.; Patel, V. F.; Powers, D.; Rose, P.; Tudor, Y.; Turci, S. M.; Welcher, A. A.; Zack, D.; Zhao, H.; Zhu, L.; Zhu, X.; Ghiron, C.; Ermann, M.; Johnston, D.; Saluste, C.-G. P. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5′,4′:5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): Synthesis, SAR, and in vivo anti-inflammatory activity J. Med. Chem. 2008, 51, 1637-1648 10.1021/jm701095m
45. Hammond, M.; Kallander, L. S.; Lawhorn, B. G.; Philp, J.; Sarpong, M. A.; Seefeld, M. A. Azolopyrimidine compounds as kinase inhibitors and their preparation and use in the treatment of disesases and methods. PCT Int. Appl. WO2011149827, 2011.
46. Casillas, L. N.; Chakravorty, S. J.; Charnley, A. K.; Eidam, P.; Haile, P. A.; Hughes, T. V.; Jeong, J. U.; Kang, J.; Lakdawala, S. A.; Leister, L. K.; Marquis, R. W.; Miller, N. A.; Price, D. J.; Sehon, C. L.; Wang, G. Z.; Zhang, D. Preparation of indazolyl-substituted pyrimidinediamine derivatives as RIP2 kinase inhibitors. PCT Int. Appl. WO2011120025, 2011.
47. May, E. W.; Rominger, C. M.; Schaber, M. D. Assay for B-Raf activity based on intrinsic MEK ATPase activity. PCT Int. Appl. US 20060211073, 2006.
48. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement J. Appl. Crystallogr. 1997, 30, 1022-1025 10.1107/S0021889897006766
49. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In Methods in Enzymology; Carter, C. W., Jr.; Sweet, R. M., Eds.; Academic Press: New York, 1997; pp 307-326.
50. Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132 10.1107/S0907444904019158
51. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255 10.1107/S0907444996012255